Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 07:01pm CEST
   By Peter Loftus 
   Of  
 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
06/22 BRISTOL MYERS SQUIBB : Trademark Application for "ELZITUDE" Filed by Bristol-Mye..
06/22 BRISTOL MYERS SQUIBB : An Application for the Trademark "EMKELOS" Has Been Filed..
06/22 BRISTOL MYERS SQUIBB : to Announce Results for Second Quarter 2017 on July 27
06/22 BRISTOL MYERS SQUIBB : Extended Follow-Up Data Evaluating Opdivo nivolumab Shows..
06/22 BRISTOL MYERS SQUIBB : Supreme Court ruling could make it harder to file class-a..
06/21 BRISTOL MYERS SQUIBB : Announces the Expiration of its Cash Tender Offer
06/20 BRISTOL MYERS SQUIBB : Announces the Pricing Terms of its Cash Tender Offer For ..
06/20 BRISTOL MYERS SQUIBB : In WLF Victory, Supreme Court's Bristol-Myers Decision Li..
06/20DJBRISTOL MYERS SQUIBB : Drug Suits Suffer Setback -- WSJ
06/20 U.S. Supreme Court again limits where companies can be sued
More news
Sector news : Pharmaceuticals - NEC
12:20p China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/22 BIOTECH FORUM DAILY DIGEST : Biotech Breaks Out! Spotlight On Aclaris Therapeuti..
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 TAKEOVER RUMORS DE JOUR : Pfizer taking out Bristol-Myers, ACADIA Pharma
Advertisement
Financials ($)
Sales 2017 20 264 M
EBIT 2017 5 470 M
Net income 2017 4 636 M
Debt 2017 74,3 M
Yield 2017 2,76%
P/E ratio 2017 20,43
P/E ratio 2018 18,69
EV / Sales 2017 4,66x
EV / Sales 2018 4,49x
Capitalization 94 447 M
More Financials
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,1 $
Spread / Average Target -0,34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Laurie H. Glimcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-1.90%94 447
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results